Many of us perceive board cert ificat ion as passing the wr itten and ora l exa ms given by the American Board of Otolaryngology (A BOto). The certification process actually begins when a res ident enters training. Th e resident mu st register with the ABOto so we can track his/her progress. Annua lly, the program director compl etes a form indicating the pro gress the resident is making and assuring that the resid ent receives credit for that year of training. At the res idency completion, the program director must then sign the resid ent' s application to take the exa mination, affir ming that the resident is medic ally and professionally qu alified .
In the past, once a candidate passed the exa ms and became certified by the ABOto, no further exa minat ions or assessmen ts were required to maintain cert ificat ion. In 2002 , based upon direc tion from the American Board of Medical Specialties (A BMS), the A BOto began issuing only time-limited ce rtifica tes that expire in 10 years and must be renewe d. All diplom ates with time-limited certificates must participate in Mai ntenance of Certification (MaC), a prog ram being developed by eac h ofthe memb er boards of the ABMS. Dipl om ates who hold timeless certificates and participate in MaC can do so without j eopardizi ng their time less certificates.
Th e stimulus for this change is the increasing national focus on healthcare quality. The A BMS and its memb er boards, along with the state medic al-lic ensing boards, are responsible for the assessmentthat individu al physicians are practicing modem, quality medicine.After careful deliberation, the ABMS developed and mand ated that all memb er boards deve lop specialty-specific MaC pro gram s.
Each MaC program consists of four parts :
I. Professional stan ding II. Continuing educat ion/self-assessment III. Cog nitive exa minatio n IV. Performance in practice
The current status of each of these components is as follows:
• All partic ipan ts must have privi leges at a hospital or ambu latory surgery ce nter. Those who do not must certify the privileges were not lost due to an adverse act ion.
II. Continuing ed uca tion/self-as sess me nt
• Previously, ea ch partic ipa nt was required to complete 100 hour s of CME every two years and report the numb er of hour s in an annual rep0l1. Sixt y percent of the hours were required to be in oto laryngology. However, the A BOto has applied to the A BMS to change the CME requirement to one in which the part icipant must meet his/he r state licensure CME requ irement.
• Eac h part icipant m ust peri od icall y pa rticipate in Internet-b ased se lf-assessment mo dules . The A BOto is in the process of deve loping a prototype self-assessme nt mod ule that should be avai lable in 2007 . More modules wi ll be develo ped in a variety of areas to serve the wide diversity of prac tice focuses in otolaryngology. There is no pass/fail on the modul es; they are to be used to identify areas of weakness that ca n serve as a gu ide for a se lf-study prog ram .
III. Cognitive examination
• Atthe end ofthe l O-year MaC cycle, the participant will be required to take and pass a computer-based exam that is clinic ally oriented. Because there is such a wide diver sity of practice focuses in oto laryngo logy, the ABOto exa m will consist of two modul es. Th e first is a core modul e that includes material that all otolary ngo logists should know such as patient safety, antibio tics, anesthetics, etc. Th e second module wi ll be selected by the part icipant base d on his/her prac tice focu s. Passing the examination wi ll renew the primary certificate and not imply special expertise in a give n area of oto laryngology.
Th e special ty mo dules wi ll include :
Dipl omates who are subcertified in Ne urotology or ). An improvement in nasal symptoms may be noted in patients wi thi n to hours of first using RHINOCORT AQUA NasalSpray. Thistimetoonset issupportedbyanenvi ronmental exposureunit studyinseasonal allergic rhini tis pat ients which demonstrated that RHiNOCORTAQUA Nasal Sprayled to a stat istically significant improvement innasalsymptoms compared toplacebo by 10hours. Furt hersupport comes from acli nical study of patients wi thperenn ial allergicrhinitiswhichdemonstratedastatisticallysignificant improvement innasal symptoms for both RHINOCORTAQUA Nasal Spray andfortheactive comparator (mometasone furoate)co mparedto placebo by 8 hours. Onset wasalso assessed in this study withpeak nasal inspirat ory flow rateand this endpointfailed to show efficacy for either active treatment. Although statistically significant improvements in nasal symptoms comparedtopl acebowerenotedwithin8-10hoursinthesestudi es,about one half totwothird sof theultimateclinical improvement wi thRHINOCORTAQUA Nasal Spray occurs over thefirst1-2 days,andmaximum benefit maynot beachieveduntilapproximately2weeksaft er ini tiationof treatment. Initi alassessment forresponseshould be made during this time frame and periodically until the patient's symptoms arestabi lized. The patient should take the medi cationas directed and should not exceed the prescribed dosage. The pati ent should contact the physician if symptoms donot improve after twoweeks, or if theconditionworsens. Patientswho experience recurrent episodes of epistaxis (nosebleeds) or nasal septum discomfort whiletakingthismedicationshouldcontact their physi ci an. For proper useofthis unit andtoattain maximum improvement.thepatient shouid read and followtheaccompanying patient instructions carefully. It is important toshake the bott lewell beforeeach use. TheRHINOCORTAQUA Nasal Spray 32mcg bottle has been fill ed wi th an excess to accommodate the primi ngactivity. The bottle should be di scarded after 120 spraysfollowing initi al priming, si nce theamount of budesonidedelivered per spray thereafter may be substantially less than the labeled dose. Do nottransfer any remaining suspensionto another bottle. Drug lnterccticns: Themain route of metabolism of budesonide, as well as othercorticosteroi ds,isviacytochrome P450 (CYP) isoenzyme 3A4 (CYP3A4). Afterorai administration ofketoconazole, apotent inhibitor ofCYP3A4, themean plasmaconcentration of orally admini stered budesonideincreased bymore than seven-fold. Concomitant administration 01 other knol'lO inhibitors of CYP3A4 (eg, itraconazole, clarithromycin, erythromycin, etc.) may inhibit the metabolism of,and increase the systemic exposureto,budesonide (see WARNINGSand PRECAUTI ONS, General). Careshould be exercised whenbudesonide iscoadministeredwith long-termketoconazole and other known CYP3A4 inhibitors. Omeprazole, aninhibi tor of CYP2CI9, didnot haveeffectsonthe pharmacokinelics of oral budesonide, whil ecimetidine, primarilyan inhibitor of CYP1 A2, causedasl ight decrease inbudesonide clearance andcorresponding increase inits oral bioavailability_Carcinogenesis, Mutcgenesis, Impairment of Fertility: Ina~' I O -year study inSprague-Dawley rats, budesonide caused a statist ically significant increaseinthe inci denceot gliomasinthe male rats recei ving an oral dose of 50 mcglkg (approximately twicethe maximum recommended dai ly intranasal dose in adults andchildren on amcglm 2 basis). Notumorigenicitywas seeninmaleand femal eratsatrespectiveoral doses up to25and 50mcglkg(approximatelyequal toand~' I O times themaximumrecommendeddailyintranasal dose inadults andchildren on amcglm 2 basis, respectivel y). Intwoadditional two-year studies inmal eFischer andSprague-Dawley rats, budesonide caused nogliomasat anoral doseof 50mcglkg(approximatelytwicethe maximum recommended daily int ranasal dose inadull s and childr en on a mcg/m 2 basis). However , in male Sprague-Oawley rats, budesonide causedastatist icall ysignificantincreaseintheincidence of hepatocellulartumorsat anoral dose of 50mcglkg(approximately twice the maximum recommended daily intr anasal dose in adults and chil dren on a mcglm 2 basis). The concurrent ref erencecorticosteroids (prednisolone and triamcinol oneacetonide) inthesetwostudiesshowed simi lar findings. In a 91-week studyin mi ce, budesonide caused no treatment-related carcinogenici ty at oral doses upto 200'mcglkg (approximately 3 times the maximum recommended daily intranasal dose in adults and children on a mcglm 2 basis). Budesonidewas not mutagenic or clastogenic in si x different test systems: Ames Salmonellaf microsome plate test, mouse micronucl eustest. mouselym phomatest, chromosomeaberrat ionlestinhuman lymphocytes, sex-linkedrecessivelethaltest in Drosophilamel anogaster, and DNArepairanalysisinrat hematocyt eculture. In rats, budesonide causedadecrease in prenatalviabili tyandviabilityofthepups at birthand during lactation, along wi tha decreaseinmaternal body-weightgain, at subcutaneousdosesof20mcglkgandabove (lessthanthemaximumrecommended daily int ranasal dose inadul ts on a mcg/m 2 basi s). No such effects were noted at 5 mcglkg (less thanthe maximum recommended daily intranasal dose in adults on a mcglm 2 basis). Pregnancy: Ter at ogenic Elf ects: Pr egnancy Category B: The impact of budesonide on human pregnancy outcomes has been evaluated through assessments ofbirthregistries linked wi th maternal usageof inhaled budesonide (ie,PULMICORT TURBUHALER) andintranasall y administered budesonide(ie, RHINOCORT AQUANasal Spray). The results from population-based prospectivecohort epidemiol ogicalstudiesreviewing datafromthreeSwed ish registriescoveringapproximately99% of the pregnancies from 1995-2001 (i.e., SwedishMedical 8irth Registry; Registry of Congenital Malformat ions; ChildCardiology Registry) indicatenoincreased risk for overall congenital malformations from theuseofinhaledor intranasal budesonide during early pregnancy. Congenital malformations were studied in 2,014infants born to mothers reporting the useofinhaled budesonideforasthma in early pregnancy (usually 10-12weeks after the last menstrual period), the periodwhen most major organ malformations occur.1 The rateof overall congenital malformations was similarcompared tothegeneral population rate(3.8 %vs. 3.5%, respectively). Thenumber ofinfants born with orofacialclefts andcardiac defects was similar to the expected number in the general population (4 children vs. 3.3and 18childrenvs. 17-18, respectively). In afollow-on study bringing the total number of infants to 2,534, the rateof overall congenital malformations among infantswhosemothers wereexposedto inhaled budesonide during earlypregnancy was notdifferent from theratefor allnewbornbabies duringthe sameperiod(3.6%).2 A third study from the Swedish Medical 8irthRegistry of 2,968 pregnancies exposed to inhaled budesonide, the majorityof which werefirsttrimester exposur es, reportedgest at ional age, birthweight, birth length, stillbirths, and mul tiplebirthssimilar for exposedinfants comparedtononexposed infants.3Congenital malformationswerestudied in 2,113infants born to mothers reporting the useof intranasal budesonide inearly pregnancy. Therateof overall congenital malformations was similarcompared to the general population rat e (4.5%vs. 3.5%, respectively). The adjusted odds rat io (OR) was 1. 06 (95%CI 0.86-1.31). The number of infants born withorofacial cleftswas simi lar to theexpected number inthegeneral population (3 childrenvs. 3, respectively). Thenumber of infants born with cardiac defects exceeded that expected in the general population(28 children vs. 17.8 respectively). Thesystemic exposure from intranasal budesonide is 6-fold less than from inhaled budesonide and an associat ion of cardiac defects was not seen wi th higherexposures of budesonide. As withother corticosteroids, budesonide was teratogenicand embryocidal in rabbits and rats. Budesonide produced fetal loss, decreased pup weights, and skeletal abnormalities at subcutaneous dosesof 25mcglkginrabbitsand500mcglkg inrats (approximately2and16times themaximumrecommended daily intranasal doseinadultson amcg/m 2 basis). Inanother study in rats, no teratogenic or embryocidal effectswereseen at inhalationdoses upto250 mcglkg (approximately8times themaxi mum reco mmended dail y intr anasal dose in adults on a mcg/m 2 basis). Experiencewith oral corticosteroids sincetheir introductioninpharmacologic, as opposed tophysiol ogicdosessuggests that rodentsaremoreprone toteratogenic effects from corticosteroids than humans. In addition, because there is an increase in corticosteroid production during pregnancy, most womenwill requirealower exogenouscorticosteroiddose and many will not need corti costeroidtreatment during pregnancy. Despi tetheanimal findings, it would appear that thepossibi lityof fetalharmis remote if the drug isused during pregnancy. Nevertheless, becausethestudies inhumanscannot ruleout thepossibility of harm, RHINOCORT AQUA shoul d beused during pregnancy only if cl early needed. Nonteratogenic Elfects: Hypoadrenalism may occur in int ants born of mothers receiving corticosteroids during pregnancy . Such infants should becarefullyobserved. Nursing Mothers: It is not known whether budesonide is excreted in human milk. Because other corticosteroidsare excreted in human milk, caution should be exercised when RHINOCORT AQUA Nasal Sprayisadministeredtonursingwomen. PediatricUse: Safetyandeff ectivenessinpediatricpatients below6 yearsof age havenot been established.Controlled cli ni cal studies have shown that intranasal cort icosteroids may cause areductioningrowt hvelocityinpediatric patients. Thiseffect hasbeen observed inthe absenceoflaboratory evidence ofhypot halamic-pituitary-adrenal(HPA)-axissuppression, suggesting thatgrowthvelocity isamoresensitiveindicatorof systemiccort icosteroid exposure in pediat ric patients thansome commonly usedtestsofHPA-axis function. The long-term effects of thi s reduction in growth velocity associated wit h intranasal cort icoster oids, including theimpact onfinal adult height, areunknown. Thepotential for"catchup" growth foll owingdiscontinuation of treatment with intranasal corticosteroids has not been adequately stucied, The growth of pediatr ic patients receivingint ranasal corticosteroids, includingRHINOCORT AQUANasal Spray, shouldbe monitored routinely(eg,via stadiometry). The potential growth effects of prolonged treatment should be weighed against clinical benefits obtainedand the availability ofsafe andeffectivenoncorticosteroidtreatment al ternat ives. To mi nimize thesystemic effects of intranasal cort icosteroids, including RHINOCORT AQUA Nasal Spray, eachpatient shoul d be titratedtothe lowest dose that effectively controls hislher symptoms. A one-yearplacebo-controlled clinical g ro l '~h study was conductedin229pedi atricpatients(ages4through8yearsof age) toassess theeff ect of RHINOCORTAQUA (singl edaily doseof64 mcg, therecommendedstarting dosefor childrenages 6yearsandabove) ong ro l '~h velocity. From apopul ationof t41 patientsreceiving RHINOCORTAQUA Nasal Spray and 67 receiving placebo, the pointestimate forgrowthvelocitywith RHINOCORTAQUANasalSpraywas 0.25cmlyear lower than thatnotedwithpl acebo(95% confidenceinterval rangingfrom 0.59 cmlyear lower thanplaceboto0.08cmlyear higher thanplacebo). The potential for RHINOCORTAQUAtocause g r o l '~h suppressi oninsusceptibl epatientsorwhengivenat dosesabove64 mcg dailycannot beruledout.Therecommendeddosagerangeinpat ients 6to11yearsof age is64to128mcg per day (seeDOSAGEANDADM INISTRATION). Geri atricUse: Of the2,461patientsinclinical studies of RHINOCORTAQUA Nasal Spray, 5% were 60years of age andover . No overall differences in safety or effectiveness were observed between these subjects and younger subjects, except for an adverse event reporting frequency ot epistaxis which increasedwithage. Further, other reported clinical experience has not identified any other differences in responses betweenelderlyand younger patients, butgreat er sensi tivity of some older individuals cannotberuled out.
ADVERSE REACTION5
The incidence of common adverse reactions is based upon two U.S. and five non-U.S. controlled clinical tri als in 1,526patients1110 femalesand239 maleslessthan 18yearsofage, and635 femalesand 542males 18yearsofage andolder] treatedI'lith RHINOCORTAQUA Nasal Sprayat dosesupto400 mcg on ce daily for3-6 weeks. Th etable belowdescribesadverseeventsoccurring at an incidence of 2%or greater and morecom mon among RHINOCORT AQUANasal Spray-treated patients than in pl acebo-treatedpatientsincontroll edclinical trials. Theoverall incidence 01 adverse event swas similarbet ween RHINOCORTAQUAand placebo. Sleep Medicine wi ll take those respective modul es, which wi ll renew their primary as we ll as their subspecialty certifica te.
IV. Per form anc e in practice
This part of MOC is pro bab ly the mos t imp ortant because it wi ll meas ure the act ual practice ofmedicine. This is a very difficult concept, and there are no good metrics avai lab le at this tim e. However, all A BMS boards are working on deve lopi ng this par t. It is likely that Part IV will be useful also in the eva luatio n processes that are be ing mand ated by insurers, Medicare/Me dicaid, and state licensing boards. This par t of MOC may also fulfill req uirements for deve loping Pay-for-Performa nce programs. The ABOto's plan is to deve lop a process that is mini ma lly intrusive, accurate, and costeffective.
Maintenance of Certificatio n applies to all diploma tes certified in 2002 and thereafter, including subspecialty certificate ho lders . In additio n, the directors of the American Board of Oto laryngology have volu ntari ly agree d to part icipate in MOC. The state licensing boards are in the process of deve loping a Maintenance of Licensure program that para llels MOC. It is felt that the states wi ll req uire participation in their MOL program to maintain a state lice nse . However, the state licensing boards have indica ted that participation in the ABMS MOC program wi ll fulfill their MOL requirements .
When we were in medical schoo l and residency, our performance was reviewed reg ularly in the for m of tests, rotation eva luatio ns, and other mec hanisms. Ultimately, we passed the ABO to exa mination and became certified but without any subseq uent forma l eva luation to help assure ourse lves and the public that we were staying curre nt on the latest medical knowledge . The vast majori ty of certified otolaryngologists provide exce llent care. However, the national move ment to improve the quali ty of hea lthcare manda tes a program to ensure we remain up-to-date, the reason for MOC. The thrust of the MOC program is a contin uo us quality improvement program. It is not intende d to be pu nitive but a stimulus for all to remain current in our prac tices . Our patients deserve no less . 
